Details

Autor(en) / Beteiligte

• Reck, Martin
• Rodríguez-Abreu, Delvys
• Robinson, Andrew G
• Hui, Rina
• Csőszi, Tibor
• Fülöp, Andrea
• Gottfried, Maya
• Peled, Nir
• Tafreshi, Ali
• Cuffe, Sinead
• O’Brien, Mary
• Rao, Suman
• Hotta, Katsuyuki
• Leiby, Melanie A
• Lubiniecki, Gregory M
• Shentu, Yue
• Rangwala, Reshma
• Brahmer, Julie R

Titel

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Ist Teil von

• The New England journal of medicine, 2016-11, Vol.375 (19), p.1823-1833

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2016

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• In a randomized trial involving patients with previously untreated advanced non–small-cell lung cancer, pembrolizumab was associated with a higher response rate, longer progression-free and overall survival, and fewer adverse events than was platinum-based chemotherapy. Approximately 23 to 28% of patients with advanced non–small-cell lung cancer (NSCLC) have a high level of programmed death ligand 1 (PD-L1) expression, which is defined as membranous PD-L1 expression on at least 50% of tumor cells, regardless of the staining intensity (i.e., a PD-L1 tumor proportion score of 50% or greater). 1 , 2 Data from the phase 1 KEYNOTE-001 and phase 3 KEYNOTE-010 studies indicated that patients with advanced NSCLC and a PD-L1 tumor proportion score of 50% or greater were more likely than those with lower tumor proportion scores to have a response to pembrolizumab, a highly selective, humanized . . .